Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
Status:
Recruiting
Trial end date:
2029-12-01
Target enrollment:
Participant gender:
Summary
This is a research study of a drug called cobimetinib in children and adults diagnosed with
Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or
does not respond to treatment. Cobimetinib blocks activation of a protein called
Mitogen-activated protein kinase (MEK) that is part of incorrect growth signals in
histiocytosis cells. Four different groups of patients will be enrolled.
Phase:
Phase 2
Details
Lead Sponsor:
Carl Allen
Collaborators:
Baylor College of Medicine Genentech, Inc. North American Consortium for Histiocytosis Texas Children's Hospital